AgilVax Triggers $2 Million Phase II Fast Track SBIR Grant and Initiates GMP Manufacturing
ALBUQUERQUE, N.M.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/NCI?src=hash" target="_blank"gt;#NCIlt;/agt;–AgilVax, Inc., a biotechnology company developing targeted antibody-based therapies for the treatment of various cancers, including…